Last reviewed · How we verify

NCT04007913

Incorporating teleCBIT Into a Hospital-Based Tic Program

Completed NA Last updated 5 July 2019
What this trial tests

NA trial testing teleCBIT in Tic Disorders in 31 participants. Completed in 15 June 2019.

Timeline
21 September 2016
Primary endpoint
15 June 2019
15 June 2019

Quick facts

Lead sponsorSan Jose State University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment31
Start date21 September 2016
Primary completion15 June 2019
Estimated completion15 June 2019
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

San Jose State University

Who can join

Adults 5 to 65, any sex, with Tic Disorders or Tourette Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm open trial of Comprehensive Behavioral Intervention for Tics (CBIT) delivered to pediatric and adult patients with persistent tic disorders in their homes via videoconferencing (i.e., teleCBIT). All participants who enroll will receive teleCBIT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evaluating the feasibility, acceptability, and preliminary effectiveness of tele-comprehensive behavior therapy for tics (teleCBIT) for Tourette syndrome in youth and adults.
    Capriotti MR, Wellen BC, Young BN, Himle MB, et al · · 2025 · cited 10× · PMID 37545359 · DOI 10.1177/1357633x231189305

Verify or expand the search:

Other recruiting trials for Tic Disorders

Currently open trials in the same condition.

Other San Jose State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04007913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing